

AMENDMENTS TO THE CLAIMS

Please amend the claims as shown below. Double brackets denote material to be deleted.

1. (Canceled)
2. (Currently amended) ~~The method of claim 1~~ A method for detecting an analyte in a sample comprising:
 - (a) contacting a sample with a fluorophore-labeled aptamer bound to a solid support, wherein the solid support is a bead;
 - (b) directly illuminating the aptamer with polarized light whereby the direct illumination of the fluorophore directly excites the fluorophore;
 - (c) measuring the fluorescence anisotropy of the fluorophore when said fluorophore-labeled aptamer is bound to said analyte; and
 - (d) identifying the presence or amount of the analyte when the measured fluorescence anisotropy is greater than an anisotropy measurement obtained in the absence of bound analyte.
3. (Previously Presented) The method of claim 2 wherein the bead is a silica bead.
4. (Previously Presented) The method of claim 2 wherein the bead has a diameter between about 1 μm and about 10 μm .
5. (Previously Presented) The method of claim 4 wherein the bead has a diameter of about 5 μm .
6. (Previously Presented) The method of claim 2 wherein the bead is suspended in solution.
7. (Previously Presented) The method of claim 2 wherein the bead is arranged in a two-dimensional array.
8. (Currently amended) The method of claim ~~[[1]]~~ 2 wherein the aptamer comprises between about 10 and about 100 nucleotides.
9. (Currently amended) The method of claim ~~[[1]]~~ 2 wherein the aptamer is labeled with a fluorophore selected from the group consisting of fluorescein derivatives, eosin derivatives, coumarin derivatives, and rhodamine derivatives.

Appl. No. : **10/628,879**
Filed : **July 28, 2003**

10. **(Previously Presented)** The method of claim 9 wherein the aptamer is labeled with carboxyfluorescein (FAM).
11. **(Currently amended)** The method of claim ~~[[1]]~~ 2 wherein the aptamer is part of an array of aptamers.
12. **(Previously Presented)** The method of claim 11 wherein the array comprises two or more addressable locations.
13. **(Previously Presented)** The method of claim 12 wherein each addressable location comprises a single type of aptamer.
14. **(Previously Presented)** The method of claim 12 wherein each addressable location comprises multiple types of aptamers.
15. **(Previously Presented)** The method of claim 14 wherein each type of aptamer is labeled with a fluorophore with unique spectral characteristics.
16. **(Currently amended)** The method of claim ~~[[1]]~~ 2 wherein the polarized light is laser light.
17. **(Currently amended)** The method of claim ~~[[1]]~~ 2 wherein the analyte is associated with a disease or disorder.
18. **(Currently amended)** The method of claim ~~[[1]]~~ 2 wherein the sample is obtained from a patient suspected of suffering from a disease or disorder.
19. **(Currently amended)** The method of claim ~~[[1]]~~ 2 wherein the analyte is a protein.
20. **(Currently amended)** The method of claim ~~[[1]]~~ 2 wherein the analyte is a metabolite.
21. **(Currently amended)** The method of claim ~~[[1]]~~ 2 wherein the sample is from a human patient and the analyte is associated with a disease or disorder.